Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2022
October 2022, Vol 12, No 10
October 2022, Vol 12, No 10
Still a Rocky Road Ahead for Biosimilars?
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
Decades ago, I remember when biosimilars were a light on the horizon. Visions of sharply discounted alternatives to reference brands that could swoop in and help patients receive the care they needed at prices that were at least 50% below current market rates.
Read More ›
Integrating Digital Health Technology into Cancer Care
By
Patricia Stewart
ESMO 2022 Highlights
Digital health technologies have the potential to help transform patient care, but there are barriers that need to be overcome, said Deb Schrag, MD, MPH, George J. Bosl Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), and Professor, Medicine, Weill Cornell Medical College, New York City, during a keynote lecture at the European Society for Medical Oncology Congress 2022.
Read More ›
Navigating the Constantly Evolving Cybersecurity Threat Landscape
By
John Squeo, MBA
;
Vikram Sukthankar, SPHIMS
Cybersecurity
With cyberattacks on health systems and medical practices omnipresent in the headlines, it can be tempting for overextended administrators and executives to reach a point in which the gravity of the situation feels overwhelming. The never-ending onslaught of breaches, malware attacks, ransomware, and data theft has left many administrators numb.
Read More ›
Nirogacestat Significantly Improves Progression-Free Survival in Patients with Desmoid Tumors
By
Patricia Stewart
ESMO 2022 Highlights
For the first time, a novel gamma secretase inhibitor has shown extremely promising results in desmoid tumors—a rare, benign, but potentially aggressive tumor type.
Read More ›
New Evidence Shows How Air Pollution May Contribute to Lung Cancer in Never-Smokers
By
Patricia Stewart
ESMO 2022 Highlights
Although it is well established that air pollution is associated with lung cancer, how this occurs has not been well described.
Read More ›
Strategies for Minimizing Some of the Most Distressing Symptoms of Cancer and Its Treatment
By
William King
ESMO 2022 Highlights
Minimizing some of the most distressing symptoms of cancer and its treatment requires systematic screening and risk assessment, as well as a focus on the underlying cause of these symptoms, according to experts at the European Society for Medical Oncology (ESMO) Congress 2022.
Read More ›
New Survey Reveals Physicians’ Attitudes Toward Biosimilars
By
Patricia Stewart
Biosimilars
A survey of US physicians who prescribe biologics to their patients revealed that 92% were confident in the safety and efficacy of biosimilars, 89% would prescribe a biosimilar to a new patient, and 80% were comfortable initiating the switching of patients who are stable on their current biologic medication to a biosimilar.
Read More ›
Key Factors Associated with Early Discontinuation of Abemaciclib Therapy in Patients with Breast Cancer in the MonarchE Trial
By
William King
Breast Cancer
Several baseline factors were associated with an increased risk for treatment discontinuation in the phase 3 monarchE clinical trial, which assessed adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive,
HER2
-negative early breast cancer, according to findings from a multivariate analysis presented during the American Society of Clinical Oncology Annual Meeting.
Read More ›
Does Oral Chemotherapy Always Equate to Financial Distress?
Advocacy
FDA-approved oral cancer drugs are not cheap, and many patients are unable to afford these promising therapies with extremely high price tags.
Read More ›
Select Ongoing Trials Currently Enrolling Patients with Breast Cancer
Clinical Trials Tracker
The following clinical trials represent a selection of key studies currently recruiting patients with breast cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes